Johnson & Johnson

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Trade Johnson & Johnson 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About JNJ

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. 

CEO
Joaquin Duato
CEOJoaquin Duato
Employees
139,800
Employees139,800
Headquarters
New Brunswick, New Jersey
HeadquartersNew Brunswick, New Jersey
Founded
1887
Founded1887
Employees
139,800
Employees139,800

JNJ Key Statistics

Market cap
426.76B
Market cap426.76B
Price-Earnings ratio
18.87
Price-Earnings ratio18.87
Dividend yield
2.88%
Dividend yield2.88%
Average volume
7.17M
Average volume7.17M
High today
$178.51
High today$178.51
Low today
$176.43
Low today$176.43
Open price
$176.65
Open price$176.65
Volume
5.67M
Volume5.67M
52 Week high
$181.16
52 Week high$181.16
52 Week low
$140.68
52 Week low$140.68

JNJ News

Benzinga 45m
Johnson & Johnson, Protagonist Study Shows Superior Skin Clearance In Psoriasis Trials

Johnson & Johnson JNJ and Protagonist Therapeutics Inc. PTGX on Wednesday released new data from the Phase 3 ICONIC-ADVANCE 1 and 2 studies of icotrokinra compa...

Johnson & Johnson, Protagonist Study Shows Superior Skin Clearance In Psoriasis Trials
Seeking Alpha 6h
J&J studies find icotrokinra more effective than deucravacitinib for psoriasis

Johnson & Johnson (NYSE:JNJ) said that data from late-stage studies showed that its oral medication, icotrokinra, was more effective compared with Bristol Myers...

J&J studies find icotrokinra more effective than deucravacitinib for psoriasis
TipRanks 8h
Johnson & Johnson reports data from Phase 3 Iconic-Advance studies

Johnson & Johnson announced new data from the Phase 3 Iconic-Advance 1 and 2 studies which assessed the superiority of icotrokinra, a first-in-class investigati...

Analyst ratings

58%

of 26 ratings
Buy
42.3%
Hold
57.7%
Sell
0%

More JNJ News

TipRanks 1d
Johnson & Johnson price target raised to $195 from $185 at JPMorgan

JPMorgan raised the firm’s price target on Johnson & Johnson to $195 from $185 and keeps a Neutral rating on the shares. The firm left its large cap biopharma e...

Seeking Alpha 2d
Henlius Biotech in talks with J&J, Roche on cancer drug: report

Shanghai Henlius Biotech (OTCPK:SGBCF) is in talks with pharmaceutical giants such as Johnson & Johnson (JNJ) and Roche Holding AG (OTCQX:RHHBY) about selling t...

Henlius Biotech in talks with J&J, Roche on cancer drug: report
Simply Wall St 2d
How Recent FDA Approval and Study Results Could Shape Johnson & Johnson’s Oncology Outlook

In the past week, Johnson & Johnson announced FDA approval of INLEXZO for BCG-unresponsive non-muscle invasive bladder cancer and published Phase 3 MARIPOSA stu...

How Recent FDA Approval and Study Results Could Shape Johnson & Johnson’s Oncology Outlook
Benzinga 5d
Jim Cramer Says Johnson & Johnson Stock Could Power Through $200 Next

Despite ongoing legal battles related to its talc products, Johnson & Johnson JNJ stock has climbed over 23% year-to-date. CNBC’s Jim Cramer on Thursday attrib...

Jim Cramer Says Johnson & Johnson Stock Could Power Through $200 Next

People also own

Based on the portfolios of people who own JNJ. This list is generated using Robinhood data, and it’s not a recommendation.
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer.